熱門資訊> 正文

周六报道，Cogent Biosciences在AAAAI 2026上重点介绍了SUMMIT数据，Bezuclastini在48周时使平均TSB降低-32.0个百分点，99%的人血清胰蛋白酶降低了至少50%

2026-03-02 15:51

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms
99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalization
Strong evidence of bezuclastinib's potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。